Phase I/II study of erlotinib (Tarceva) and cetuximab (Erbitux) in advanced solid tumours, with emphasis on non small cell lung cancer (NSCLC).

Trial Profile

Phase I/II study of erlotinib (Tarceva) and cetuximab (Erbitux) in advanced solid tumours, with emphasis on non small cell lung cancer (NSCLC).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Cetuximab (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 27 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 11 Mar 2013 Planned end date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 09 May 2012 Actual patient number is 64 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top